| Biomarker ID | 1598 |
| PMID | 26254378 |
| Year | 2015 |
| Biomarker | −2proPSA |
| Biomarker Basis | Concentration Based (ng/L) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa [BPH: 16.0 (3.0-81.0); PCa: 21.0 (4.0-135.0)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 150 patients with Benign Prostatic Hyperplasia and 113 with Prostate cancer were selected for the study |
| Senstivity | Cut off 4μg/L: 11%; Cut off 10 μg/L: 79% |
| Specificity | Cut off 4μg/L: 96%; Cut off 10 μg/L: 23% |
| AUC | 0.62292 |
| Accuracy | NA |
| Level Of Significance | p = 0.0004 |
| Method Used | Chemiluminescence |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |